 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || UCB0022 / UCB
Trial completion date, Trial primary completion date, Metastases: ATLANTIS: A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease (clinicaltrials.gov) - Oct 15, 2024
P2, N=189, Recruiting, Sponsor: UCB Biopharma SRL
Trial completion date: Dec 2024 --> Apr 2025 | Trial primary completion date: Dec 2024 --> Mar 2025
- ||| UCB0022 / UCB
Enrollment open, Metastases: ATLANTIS: A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease (clinicaltrials.gov) - Nov 21, 2023
P2, N=189, Recruiting, Sponsor: UCB Biopharma SRL
Trial completion date: Dec 2024 --> Apr 2025 | Trial primary completion date: Dec 2024 --> Mar 2025 Not yet recruiting --> Recruiting
- |||| UCB0022 / UCB
New P2 trial, Metastases: ATLANTIS: A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease (clinicaltrials.gov) - Sep 28, 2023
P2, N=189, Not yet recruiting, Sponsor: UCB Biopharma SRL
- UCB0022 / UCB
Safety and tolerability of UCB0022, a dopamine 1 (D1) receptor modulator in people with Parkinson () - Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_2113;
P1
No new safety concerns were identified; there were no deaths, serious TEAEs or TEAEs of severe intensity reported in any part of the study. Titration reduced the incidence and severity of TEAEs and showed fewer effects on vital signs.
- ||| UCB0022 / UCB
Trial completion: A Study to Test the Safety, Tolerability, and Blood Levels of UCB0022 in Healthy Participants and Participants With Parkinson's Disease (clinicaltrials.gov) - Mar 30, 2023
P1, N=100, Completed, Sponsor: UCB Biopharma SRL
Titration reduced the incidence and severity of TEAEs and showed fewer effects on vital signs. Active, not recruiting --> Completed
- || UCB0022 / UCB
Enrollment closed: A Study to Test the Safety, Tolerability, and Blood Levels of UCB0022 in Healthy Participants and Participants With Parkinson's Disease (clinicaltrials.gov) - Feb 23, 2023
P1, N=100, Active, not recruiting, Sponsor: UCB Biopharma SRL
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- UCB0022 / UCB
Preclinical characterization of UCB0022, an oral, brain penetrant, selective, clinical-stage positive allosteric modulator of the dopamine 1 receptor (D1 PAM) (Poster Station: GPT 12) - Sep 22, 2022 - Abstract #MDSCongress2022MDR_Congress_1053;
UCB0022 is a selective and potent D1 PAM, able to improve motor disability in MPTP-treated macaques as effectively as levodopa, but with a reduction in severe dyskinesia. Together with favorable PK and safety profiles, these data supported the progression of UCB0022 to first-in-human studies.
- || UCB0022 / UCB
Trial completion date, Trial primary completion date: A Study to Test the Safety, Tolerability, and Blood Levels of UCB0022 in Healthy Participants and Participants With Parkinson's Disease (clinicaltrials.gov) - Sep 9, 2022
P1, N=84, Recruiting, Sponsor: UCB Biopharma SRL
Together with favorable PK and safety profiles, these data supported the progression of UCB0022 to first-in-human studies. Trial completion date: May 2022 --> Dec 2022 | Trial primary completion date: May 2022 --> Dec 2022
- ||| UCB0022 / UCB
Enrollment open: A Study to Test the Safety, Tolerability, and Blood Levels of UCB0022 in Healthy Participants and Participants With Parkinson's Disease (clinicaltrials.gov) - May 6, 2021
P1, N=84, Recruiting, Sponsor: UCB Biopharma SRL
Trial completion date: May 2022 --> Dec 2022 | Trial primary completion date: May 2022 --> Dec 2022 Not yet recruiting --> Recruiting
- ||| UCB0022 / UCB
New P1 trial: A Study to Test the Safety, Tolerability, and Blood Levels of UCB0022 in Healthy Participants and Participants With Parkinson's Disease (clinicaltrials.gov) - Apr 29, 2021
P1, N=84, Not yet recruiting, Sponsor: UCB Biopharma SRL